Pfizer Inc. Drug Gets Thumbs-Down From U.K. Advisory Committee

LONDON (MarketWatch) -- A U.K. advisory committee on Tuesday said a new Pfizer Inc. inhaled insulin drug shouldn't be purchased by Britain's health service as the company's data doesn't show it's any better than existing alternatives.